Design and anti-tumor activity of self-loaded nanocarriers of siRNA

Stratton, 2009, The cancer genome, Nature, 458, 719, 10.1038/nature07943 Kaczmarek, 2017, Advances in the delivery of RNA therapeutics: from concept to clinical reality, Genome Med., 9, 60, 10.1186/s13073-017-0450-0 Zuckerman, 2015, Clinical experiences with systemically administered siRNA-based therapeutics in cancer, Nat. Rev. Drug Discov., 14, 843, 10.1038/nrd4685 Bobbin, 2016, RNA interference (RNAi)-based therapeutics: delivering on the promise?, Annu. Rev. Pharmacol. Toxicol., 56, 103, 10.1146/annurev-pharmtox-010715-103633 Aishwarya, 2018, Advances in siRNA delivery in cancer therapy, Artif. Cells Nanomed. Biotechnol., 46, 274, 10.1080/21691401.2017.1307210 Dominska, 2010, Breaking down the barriers: siRNA delivery and endosome escape, J. Cell. Sci., 123, 1183, 10.1242/jcs.066399 Thomas, 2003, Progress and problems with the use of viral vectors for gene therapy, Nat. Rev. Genet., 4, 346, 10.1038/nrg1066 Liu, 2002, Development of non-viral vectors for systemic gene delivery, J. Control. Release, 78, 259, 10.1016/S0168-3659(01)00494-1 Buyens, 2012, Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design, J. Control. Release, 158, 362, 10.1016/j.jconrel.2011.10.009 Pack, 2005, Design and development of polymers for gene delivery, Nat. Rev. Drug Discov., 4, 581, 10.1038/nrd1775 Tai, 2017, Functional peptides for siRNA delivery, Adv. Drug Deliv. Rev., 110, 157, 10.1016/j.addr.2016.08.004 Reches, 2003, Casting metal nanowires within discrete self-assembled peptide nanotubes, Science, 300, 625, 10.1126/science.1082387 Song, 2004, Synthesis of peptide-nanotube platinum-nanoparticle composites, Chem. Commun., 1044, 10.1039/B402126F Yan, 2007, Transition of cationic dipeptide nanotubes into vesicles and oligonucleotide delivery, Angew. Chem., 119, 2483, 10.1002/ange.200603387 Guan, 2019, Delivery of Survivin siRNA Using Cationic Diphenylalanine Vesicles, Chem. Res. Chin. Univ., 35, 10.1007/s40242-019-8184-8 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387 Hobbs, 1998, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci., 95, 4607, 10.1073/pnas.95.8.4607 Ryan, 2008, Advances in PEGylation of important biotech molecules: delivery aspects, Expert Opin. Drug Deliv., 5, 371, 10.1517/17425247.5.4.371 Abuchowski, 1977, Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol, J. Biol. Chem., 252, 3578, 10.1016/S0021-9258(17)40291-2 Klibanov, 1990, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 268, 235, 10.1016/0014-5793(90)81016-H Su, 2017, Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy, Nat. Commun., 8, 15507, 10.1038/ncomms15507 Dutta, 2017, PEG coated vesicles from mixtures of Pluronic P123 and L-α-phosphatidylcholine: structure, rheology and curcumin encapsulation, J. Chem. Soc. Faraday Trans., 19 Borrelli, 2018, Cell penetrating peptides as molecular carriers for anti-cancer agents, Molecules, 23, 295, 10.3390/molecules23020295 Alhakamy, 2013, Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes, Mol. Pharm., 10, 1940, 10.1021/mp3007117 Bakan, 2017, Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery, Colloids Surf. B Biointerfaces, 158, 175, 10.1016/j.colsurfb.2017.06.028 Rothbard, 2004, Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells, J. Am. Chem. Soc., 126, 9506, 10.1021/ja0482536 Mita, 2008, Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics, Clin. Cancer Res., 14, 5000, 10.1158/1078-0432.CCR-08-0746 Groner, 2014, Targeting survivin in cancer: novel drug development approaches, BioDrugs, 28, 27, 10.1007/s40259-013-0058-x Wang, 2015, Effect of survivin siRNA on biological behaviour of breast cancer MCF7 cells, Asian Pac. J. Trop. Med., 8, 225, 10.1016/S1995-7645(14)60320-5 Hu, 2012, Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly, Biomaterials, 33, 6580, 10.1016/j.biomaterials.2012.05.060 Zhang, 2015, Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo, Mol. Med. Rep., 11, 639, 10.3892/mmr.2014.2729 Cheng, 2005, Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721, World J. Gastroenterol., 11, 756, 10.3748/wjg.v11.i5.756 Song, 2013, RNA interference-mediated inhibition of survivin and VEGF in pancreatic cancer cells in vitro, Mol. Med. Rep., 7, 1651, 10.3892/mmr.2013.1361 Paduano, 2006, Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells, Mol. Cancer Ther., 5, 179, 10.1158/1535-7163.MCT-05-0132 Behrendt, 2016, Advances in Fmoc solid‐phase peptide synthesis, J. Pept. Sci., 22, 4, 10.1002/psc.2836 Murugan, 2015, Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures, Int. J. Nanomedicine, 10, 2191 Gary, 2013, The effect of N/P ratio on the in vitro and in vivo interaction properties of PEG ylated poly [2‐(dimethylamino) ethyl methacrylate]‐B ased siRNA complexes, Macromol. Biosci., 13, 1059, 10.1002/mabi.201300046 Dalby, 2004, Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications, Methods, 33, 95, 10.1016/j.ymeth.2003.11.023